Get the Stockscreener App
4.01
0.50%
-0.02
After Hours:
4.05
0.04
+1.00%
Edesa Biotech Inc stock is traded at $4.01, with a volume of 15,496.
It is down -0.50% in the last 24 hours and down -9.89% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
See More
Previous Close:
$4.03
Open:
$4.04
24h Volume:
15,496
Relative Volume:
0.23
Market Cap:
$38.66M
Revenue:
-
Net Income/Loss:
$-10.44M
P/E Ratio:
-2.9912
EPS:
-1.3406
Net Cash Flow:
$-7.72M
1W Performance:
-3.14%
1M Performance:
-9.89%
6M Performance:
-38.96%
1Y Performance:
+64.34%
1-Day Range:
$3.97
$4.095
1-Week Range:
$3.90
$4.235
52-Week Range:
$0.72
$20.32
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
4.01 | 38.66M | 0 | -10.44M | -7.72M | -1.3406 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Edesa Biotech Inc Stock (EDSA) Latest News
EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech? - Stocktwits
Edesa Biotech Stock Price Forecast. Should You Buy EDSA? - StockInvest.us
Edesa Biotech (EDSA) Slips 3.40% to $3.98, Drifting Toward Support at $3.78Low Risk Entry Stocks - careplusvn.com
Edesa Biotech completes US$3.5 million private placement - Fasken
Stonepine Capital Management, LLC Expands Edesa Biotech Inc (EDS - GuruFocus
Insider share moves at Edesa Biotech (EDSA) detailed in new SEC filing - Stock Titan
Velan Capital Investment Management LP Expands Edesa Biotech Inc (EDSA) Stake - GuruFocus
Edesa Biotech (EDSA) Dips 3.5% as Shares Test Key Support ZoneDay Trade Opportunities - dars.gov.et
EDSA Should I Buy - Intellectia AI
EDSA Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued Clinical-Stage InvestmentEPS Revision Trend - vinanet.vn
Stonepine group discloses sub-10% Edesa Biotech (NASDAQ: EDSA) position - Stock Titan
Velan Capital lifts Edesa Biotech (EDSA) stake to 9.99% with warrant leverage - Stock Titan
EDSA: Recruitment in Phase 2 Vitiligo Study Set to Get Underway - Yahoo Finance
Edesa Biotech completes US$25 million public offering - Fasken
Edesa (EDSA) Results Review: The Bottom-Line Figure Trails Its Comparison at the Close; Price Reaction: Shares Close 17.22% Lower in Latest TradingInterim Report - vinanet.vn
Edesa Biotech Enters Underwriting Deal With Guggenheim for $23.1M Equity Offering - TradingView
Edesa Biotech Prices $25 Million Stock-and-Warrant Offering to Fund Drug Pipeline - finance.biggo.com
Edesa Biotech Shares Tumble 13% on $25 Million Equity Offering - finance.biggo.com
Why Did EDSA Stock Rally More Than 70% Today? - Stocktwits
Edesa (EDSA) Quarter in Focus: EPS Does Not Reach the Reported Estimate for the Current Session; Share Move - vinanet.vn
Edesa Biotech Stock Sinks After Fresh Capital Raise - TradingView
Edesa Biotech raises USD 25m to fuel vitiligo Phase II - AllSci
Edesa Biotech Raises $25 Million in Public Offering to Advance Immuno-Inflammatory Pipeline - TipRanks
Edesa Biotech prices $25M public offering at $5.50 per share By Investing.com - Investing.com Australia
Edesa Biotech prices $25M public offering at $5.50 per share - Investing.com Australia
Edesa Biotech Announces Pricing of $25.0 Million Public Offering - Yahoo Finance
Edesa Biotech stock tumbles on public offering launch By Investing.com - Investing.com Nigeria
Edesa Biotech Launches Public Offering of Common Shares, Warrants - marketscreener.com
Edesa Biotech Launches Public Offering to Fund Immuno-Inflammatory Pipeline - tipranks.com
Edesa Biotech launches public offering of common shares - Investing.com
Edesa Biotech launches public offering of common shares By Investing.com - Investing.com India
Edesa Biotech stock tumbles on public offering launch - Investing.com
Edesa Biotech Announces Proposed Public Offering of Common Shares and Warrants - Quiver Quantitative
Edesa Biotech Announces Proposed Public Offering - The Manila Times
Edesa Biotech(EDSA) Stock Options Chain | Quotes & News - Moomoo
Edesa Biotech Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
EDSA Q2 2026 Earnings: EPS Misses Consensus by 84.77% Despite Shares Rallying 5.61%Earnings Volatility Report - vinanet.vn
Brokers Set Expectations for Edesa Biotech FY2026 Earnings - MarketBeat
EDSA Q2 2026 Earnings: Wider-than-Expected Loss Amid Clinical-Stage SpendingShare Dilution Risk - vinanet.vn
EDSA Stock Soars More Than 700% So Far This Year: Wall Street Eyes Further Upside In Run Up To Acute Kidney Injury Data Reveal - Stocktwits
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results - The Manila Times
Edesa Biotech (NASDAQ:EDSA) Posts Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat
Edesa Biotech Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K EDESA BIOTECH For: 13 August By Investing.com - Investing.com South Africa
Edesa Biotech Q3 loss widens 140% to $5.4M on rising R&D spend - scanx.trade
Edesa Biotech (EDSA) loss widens to $11.9M as R&D surges and cash tightens - Stock Titan
Edesa Reports $5.4 Million Q3 Loss as EB06 Phase 2 Site Activation Begins - Quiver Quantitative
Edesa Starts Activating First Vitiligo Trial Sites as Enrollment Nears - Stock Titan
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):